Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This led to the development of exenatide, a synthetic version of exendin-4, as the first GLP-1 agonist approved for treating type 2 diabetes in 2005
doi: 10.1080/AC.70.1.3064591 24 ScaglioneRArganoCDi ChiaraTColombaDParrinelloGCorraoSet al
6 The ADA recommends that patients with prediabetes or diabetes receive individualized medical nutrition therapy, preferably from a registered dietitian, to achieve treatment goals
Resmetirom achieved this goal and received a fast-track approval by FDA
US$ 29.86
US$ 26.43
US$ 21.69
